

Briefing on speakers (Paper 3)

All-Party Parliamentary Group on Osteoporosis and Bone Health All-Party Parliamentary Group on Prostate Cancer

Oral evidence hearing

Thursday 2 July
09:45 – 11:15

Committee Room 6, Palace of Westminster

Evidence Session One

09.55 – 10.30

Lance Allen	Patient representative Lance Allen is a prominent patient advocate and trustee for PCaSO Prostate Cancer Support Organisation, a charity operating across Dorset, Hampshire, and Sussex for awareness, support and PSA testing. After being treated for prostate cancer himself following a PCaSO PSA test outcome, he now dedicates his time to raising awareness at regional events, leading PSA events in Sussex and facilitating patient support. Lance has been on hormone treatment for over 8 years and is living with the higher risk of bone density loss or fracture. He focusses on exercise and diet to maintain his overall health.
Kevin Mortimer	Patient representative Kevin Mortimer is a Professor of Respiratory Medicine and Deputy Divisional Medical Director at Aintree University Hospital in Liverpool. Kevin was diagnosed with advanced prostate cancer (lung and bone metastases) in 2024 which was treated with triplet therapy together with systemic corticosteroids and radiotherapy to his spine. In 2025 he was diagnosed with osteoporosis relating to this treatment and commenced on denosumab. He has written in detailed terms about his own diagnosis, treatment and recovery.
Dr Helena Carreira	Assistant Professor, London School of Hygiene & Tropical Medicine Dr Helena Carreira is an Assistant Professor at the London School of Hygiene & Tropical Medicine (LSHTM). She holds degrees in Nutritional Sciences from the University of Porto, Public Health from the University of Porto, and Epidemiology and Population Health from LSHTM. Dr Carreira joined the Department of Non-Communicable Disease Epidemiology in 2013. Prior to joining LSHTM, she taught Epidemiology at the University of Porto Medical School. She also worked as a Research

	Fellow at the Public Health Institute, where she looked into the determinants of gastric and oesophageal cancers, and secular trends of risk factors for cardiovascular disease in Portugal. Her research focuses on the use of electronic health records, which are routinely collected in primary care practices and hospitals in the UK, to study whether cancer survivors have different outcomes compared with people who did not have cancer. She is also interested in the effects of the COVID-19 pandemic on cancer survivorship, and has been involved in several studies including outcomes in cancer survivors.
--	---

Evidence Session Two

10.35 – 11:10

Mr Ashwin Sachdeva	Consultant Urological Surgeon, The Christie Hospital Mr Ashwin Sachdeva is a Consultant Urological Surgeon at The Christie NHS Foundation Trust and Senior Lecturer at the University of Manchester, specialising in prostate cancer. He is closely involved in the world-leading STAMPEDE trial programme and is an associate member of the European Association of Urology Prostate Cancer Guidelines Panel. He received the Prostate Cancer Foundation Young Investigator Award for research linking clinical trial data with imaging and routinely collected health data. His work has examined the long-term consequences of treatment for advanced prostate cancer, particularly the effects of hormone therapy on bone health and the risk of fractures. This research has informed national and international clinical guidance on protecting bone health in men starting hormone therapy. Through his combined roles as a surgeon and clinical researcher, he is focused on translating evidence into practical improvements in NHS care, helping men with prostate cancer live longer while maintaining their independence and quality of life. His wider research interests include imaging biomarkers, precision medicine, prostate cancer metabolism and biomarker-directed clinical trials.
Dr Xue-Yan Jiang	Consultant Clinical Oncologist, Freeman Hospital's Northern Centre for Cancer Care Dr Xue-Yan Jiang is a Consultant Clinical Oncologist at the Northern Centre for Cancer Care (NCCC), Freeman Hospital in Newcastle, specialising in prostate cancer. She co-led and co-authored the RCR national guideline on bone health in prostate cancer which was published in Spring 2026. Her current other role includes Quality and Safety Lead for oncology and haematology board, Newcastle Hospitals NHS Foundation Trust. Her clinical interests include real-world research, radiotherapy, imaging, bone health and biomarkers, alongside a strong commitment to medical education.

Dr Claire Higham	Consultant Endocrinologist, Christie Hospital Dr Claire Higham undertook a physiology degree and DPhil at Merton College, Oxford followed by completion of her medical training at Royal Free/University College London. Her junior doctor training was in London followed by higher specialist training in Manchester including a 3-year clinical research fellowship at The Christie. Dr Higham became an endocrine consultant at The Christie in 2012 where her clinical and academic work is focused on the Bone and Endocrine consequences of Cancer and Cancer treatments. She is the lead for the Bone/Endocrine research within the Manchester BRC Living With And Beyond Cancer Theme.
-------------------------	--